Omada Health (OMDA) Q2 2026 Earnings Call Transcript

Omada Health posted record Q2 results: revenue rose 43% YoY to $88M, GAAP gross margin expanded 700 bps to 73%, and GAAP net income swung to +$5M (from -$5M). Management raised full-year 2026 guidance to $334M–$340M revenue (from $322M–$330M) and $21M–$27M adjusted EBITDA (from $14M–$20M), with quarterly adjusted EBITDA at a record $11M. The balance sheet remains strong with $222M cash and zero debt, while AI-driven operating efficiency cut trailing cost to serve by >10% YoY and improved operating leverage (non-GAAP OpEx fell to 62% of revenue). Despite CFO noting H2 growth may moderate after exceptionally strong H1 enrollment, the raised guidance and second-quarter GAAP profitability support a notably positive outlook.

Analysis

The key read-through is that OMDA is transitioning from a story stock tied to GLP-1 enthusiasm into a scaled benefits platform with improving unit economics. The important signal is not top-line acceleration alone, but that longer member tenure and lower cost-to-serve are compounding together, which should expand lifetime value and make the model less promotional as the book grows. If Investor Day confirms durable gross margin above the prior long-term target and continued opex leverage into 2027, the market may need to re-rate this closer to a quality SaaS/benefits compounder than a cyclical telehealth name.

Near term, however, the setup is asymmetric in both directions because management is already warning that growth normalizes in H2 after a very strong first half. That means the stock can overshoot on optimism if investors extrapolate the quarter, but it can also de-rate quickly if member adds or EBITDA margin come in below the implied run-rate. The clean falsifier is a visible deceleration in Q3/Q4 enrollment or a cut to 2026/2027 profitability assumptions; that would signal the AI and mix benefits are not as scalable as advertised.

Second-order winners are the PBM/health-plan distribution layer and any employer-benefits platform that can bundle chronic care with pharmacy economics; losers are commoditized digital health vendors and direct-to-consumer GLP-1 players that cannot show ROI beyond medication access. The contrarian miss is that the market may still be underestimating how much of OMDA’s value now comes from non-GLP-1 chronic care and cross-sell, while simultaneously overestimating how quickly the 2027 covered-lives base converts into revenue. The HCSC expansion and investor-day timing create a good catalyst path, but much of that benefit is back-half/2027, not immediate.

Key Decisions for Investors

• Buy OMDA on any 5-8% post-earnings pullback; hold into the Sep. 10 Investor Day. Risk/reward favors upside if management proves the margin framework is structurally higher, but trim if Q3 member growth or EBITDA margin comes in below the implied cadence.
• Pair trade: long OMDA / short TDOC over the next 3-6 months. OMDA has clearer monetization leverage, better margin inflection, and a more defensible employer distribution model; TDOC remains exposed to lower-quality telehealth mix and weaker operating leverage.
• Add a watch item on OMDA for the 2027 benefit-cycle reset rather than chasing the stock for near-term H2 revenue. The HCSC covered-lives expansion and PBM pipeline are real, but the revenue inflection is more of a 2027 story; use any near-term volatility to build.
• If using options, prefer a medium-dated OMDA call spread into Investor Day rather than outright momentum chasing. The thesis is catalyst-driven, but the second-half growth moderation means upside is likely to be stair-stepped rather than linear.